Overview


Neuropathic pain is a chronic pain condition caused owing to infection, trauma and other such dysfunctional systems in the nerves. Primary neuropathic pain syndromes include postherpetic neuralgia, painful neuropathy, painful traumatic mononeuropathy, central pain syndromes, complex regional pain syndrome and postsurgical pain syndromes. Anticonvulsants, antidepressants like tricyclic antidepressants and anaesthetics are generally prescribed for neuropathic pain.
Furthermore, antidepressants like nortriptyline and amitriptyline are primarily used for managing neuropathic pain. Additionally, the growing prevalence of chronic diseases like diabetes and cancer shall bolster the neuropathic pain management market growth. However, a dearth of awareness pertaining to the implementation of the procedure in underdeveloped regions shall impede the proliferation of the market. Conversely, rise in the number of pain centres shall boost the augmentation of the market.
By Drug Class
• Gabapentinoids
• Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants
• Combination Drugs
• Others
By Route of Administration
• Oral
• Topical
• Transdermal
By Indications
• Diabetic Neuropathy
• Trigeminal Neuralgia
• Post-Herpetic Neuralgia
• Chemotherapy-Induced Peripheral Neuropathy
• Other Indications
By Distribution Channel
• Hospital Pharmacies
• Retail/ Drug Stores
• Online Pharmacies
By Region
North America
• Europe
• Asia Pacific
• Latin America
• Middle East
Africa
The market is categorised into drug class, indication, distribution channel and region. The drug class segment is classified into tricyclic antidepressants, anticonvulsants, SNRIs, capsaicin cream, local anaesthesia, opioids, steroids and others. The tricyclic antidepressants segment is predicted to hold the largest neuropathic pain management market share during the forecasted timeframe. The indication segment is fragmented into diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others. The distribution channel segment is diversified into retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacies segment is anticipated to lead the market owing to growing investments for hospitals in developed and underdeveloped nations.
The North America region is expected to dominate the market and this can be credited to increased disposable income, rising geriatric population, a strong presence of key market players in the region.
• Baxter International Inc.
• Biogen Inc
• Bristol-Myers Squibb and Company
• Assertio Therapeutics Inc.
• Eli Lily and Company
• GlaxoSmithKline PLC
• Johnson
Johnson Services Inc.
• Pfizer Inc.
• Sanofi S.A.
• MerckCo.
• Teva Pharmaceutical Industries Ltd.

Growth prospects

SWOT analysis

Key market trends

Key data-points affecting market growth

To provide with an exhaustive analysis on the global neuropathic pain management market by drug class, by indications, by route of administration, by distribution channel and by region

To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

To evaluate and forecast micro-markets and the overall market

To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa

To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement

The customization Mobility Care offered are free of charge with purchase of any license of the report

You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Neuropathic Pain Management Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Neuropathic Pain Management Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Neuropathic Pain Management Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Neuropathic Pain Management Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Gabapentinoids
        2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
        3. Tricyclic Antidepressants
        4. Combination Drugs
        5. Others
  • 8.   Neuropathic Pain Management Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Oral
        2. Topical
        3. Transdermal
  • 9.   Neuropathic Pain Management Market, By Indications Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Diabetic Neuropathy
        2. Trigeminal Neuralgia
        3. Post-Herpetic Neuralgia
        4. Chemotherapy-Induced Peripheral Neuropathy
        5. Other Indications
  • 10.   Neuropathic Pain Management Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail/ Drug Stores
        3. Online Pharmacies
  • 11.   North America Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2022-2028
  • 12.   Latin America Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028
  • 13.   Europe Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2022-2028
  • 14.   Asia Pacific Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 15.   Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2022-2028
  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •    1. Baxter International Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Biogen Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
         4. Assertio Therapeutics Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Eli Lily and Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline PLC
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Johnson
  • 18.  Johnson Services Inc.
    •    17.7.1. Company Overview
         17.7.2. Product Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
         17.8. Pfizer Inc.
         17.8.1. Company Overview
         17.8.2. Product Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
          17.9. Sanofi S.A.
         17.9.1. Company Overview
         17.9.2. Product Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
         17.10.MerckCo.
         17.10.1. Company Overview
         17.10.2. Product Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview
         17.11.Teva Pharmaceutical Industries Ltd.
         17.11.1. Company Overview
         17.11.2. Product Portfolio
         17.11.3. SWOT Analysis
         17.11.4. Financial Overview
         17.11.5. Strategic Overview
  • 19.   Pre and Post COVID-19 Impact
    •   18.1. Positive influence on the healthcare industry
        18.2. The financial disruption of the manufacturing sector
        18.3. Impact of COVID-19 on emerging companies
        18.4. Significant mandates in the healthcare regulations initiated by administrations
        18.5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients